There is initial evidence that the choice of anesthesia can influence survival in the specific setting of coronary artery bypass grafting surgery (CABG). A recent international consensus conference included volatile agents among the few drugs/techniques/strategies that might reduce perioperative mortality in cardiac surgery and that should be further studied. Volatile anesthetics (desflurane, isoflurane and sevoflurane) have non-anesthetic pharmacological characteristics that confer cardiac protection when compared to Total IntraVenous Anesthesia (TIVA). Several randomized controlled studies were summarized in a meta-analysis that documented a reduction in perioperative cardiac troponin release and mortality in patients receiving volatile anesthetics when compared to patients receiving a TIVA. There are four published studies (Bignami et al. 2009) (De Hert et al. 2009) (Jackobsen et al. 2007) (Landoni et al. 2007) suggesting that these benefits can translate into a reduced mortality rate in patients receiving volatile agents. The level of evidence for these four studies is not high (one meta-regression, one underpowered randomized controlled study, one retrospective study and one meta-analysis of small randomized studies) and there is need for a large multicentre randomized controlled study to confirm these findings, as suggested by the international consensus conference on this topic published in 2011 (Landoni et al 2011). The purpose is to provide a large multicentre controlled randomized trial to demonstrate that volatile anesthetics can reduce 1 year mortality from 3% to 2% in patients undergoing CABG (either with or without cardiopulmonary bypass). The results of this study can support the use of volatile agents in all CABG procedures worldwide (more than 500.000 per year) with 2.500 lives saved per year (in the hypothesis that nowadays half the procedures are performed with a TIVA and that 1 year mortality can be reduced from 3% to 2% using volatile agents).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
5,400
Mohammed Bin Khalifa Bin Sulman Al-Khalifa Cardiac Center - Bahrain
Bahrein, Bahrain
Hospital das Clínicas da Faculdade de Medicina da USP - Istituto do Coracao
São Paulo, Barazil, Brazil
Dante Pazzanese Institute of Cardiology
São Paulo, Brazil
Heart Center Pontica
Burgas, Bulgaria
Beijing Anzhen Hospital, Capital Medical University
Beijing, China
mortality
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
The Second Xiangya Hospital of Central South University
Changsha, China
Wuhan Asia Heart Hospital
Hubei, China
1st Affiliated Hospital of Fourth Military University
Xi'an, China
University Hospital Dubrava
Dubrava, Croatia
General University Hospital, Charles University
Prague, Czech Republic, Czechia
...and 26 more locations